Conditions: Kidney Failure, Chronic
Keywords: Chronic Kidney Disease Phosphate Binder Phosphate Hyperphosphatemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 349
Healthy volunteers: no

Brief summary:
The purpose of this clinical study is to compare the effects of Genz-644470 with the effects of placebo and sevelamer carbonate (Renvela®) on the reduction of serum phosphorus in hyperphosphatemic chronic kidney disease participants on hemodialysis.

Detailed description:

Arms:
arm 1: Placebo matched to Genz-644470 tablet orally three times a day (TID) with meals for 3 weeks. arm 2: Genz-644470 2.4 g/day tablets dosed orally TID with meals for 3 weeks. arm 3: Genz-644470 4.8 g/day tablets dosed orally TID with meals for 3 weeks. arm 4: Genz-644470 7.2 g/day tablets dosed orally TID with meals for 3 weeks. arm 5: Sevelamer Carbonate 2.4 g/day tablets dosed orally TID with meals for 3 weeks. arm 6: Sevelamer Carbonate 4.8 g/day tablets dosed orally TID with meals for 3 weeks. arm 7: Sevelamer Carbonate 7.2 g/day tablets dosed orally TID with meals for 3 weeks.

Interventions: intervention 1: Placebo intervention 2: Genz-644470 intervention 3: Sevelamer carbonate
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document: